Some time ago I introduced Motif Bio (currently 70 Mil Market Capit.), an UK based Biotec company that pushed a phase iii trial with ICLAPRIM through... Phase III results are on the Company's Web Site. Iclaprim is likely to get a fast track approval by FDA. This years target is in the range of 80-100p. But be aware, MRSA is a multi bill. USD Market and I rather expect a takeover by the big players...